Talphera, Inc. (TLPH)

Market Cap	10.82M
Revenue (ttm)	281,000
Net Income (ttm)	-15.65M
Shares Out	17.03M
EPS (ttm)	-0.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	76,335
Open	0.618
Previous Close	0.618
Day's Range	0.604 - 0.690
52-Week Range	0.600 - 1.610
Beta	0.23
Analysts	Strong Buy
Price Target	4.50 (+608.33%)
Earnings Date	Nov 13, 2024

About TLPH

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (AR...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 14, 2011
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: TLPH
• Website: https://talphera.com

Analyst Forecast

According to 2 analysts, the average rating for TLPH stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 608.33% from the latest price.

Price Target

$4.5

(608.33% upside)

Analyst Consensus: Strong Buy